Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone

American Journal of Cardiology

Volumn 79, Issue 1, 1997, Pages 53-57

  Tieleman, Robert G ^a   Gosselink, A T Marcel ^a   Crijns, Harry J G M ^a   Van Gelder, Isabelle C ^a   Van Den Berg, Maarten P ^a   De Kam, Pieter J ^a   Van Gilst, Wiek H ^a   Lie, Kong I ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DEETHYLAMIODARONE; DRUG DERIVATIVE;

AGED; ARTICLE; BLOOD; CARDIOVERSION; ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; ECHOCARDIOGRAPHY; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES;

EID: 0030635803     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00675-3     Document Type: Article

References (29)

1. Gosselink ATM, Crijns HJ, Van Gelder IC, Hillege H, Wiesfeld ACP, Lie KI. Efficacy and safety of low dose amiodarone for long-term maintenance of sinus rhythm after electrical cardi oversion of refractory chronic atrial fibrillation or flutter. JAMA 1992;267:3289-3293.
2. Crijns HJGM, Van Gelder IC, Van Gilst WH, Hillege HJ, Gosselink ATM, Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991;68:335-341.
3. Van Gelder IC, Crijns HJGM, Van Gilst WH, Hamer HPM, Lie KI. Decrease of right and left atrial sizes after DC electrical cardioversion in chronic atrial fibrillation. Am J Cardiol 1991;67:93-95.
4. Horowitz LN, Greenspan AM, Rae AP, Kay HR, Spielman SR. Proarrhythmic responses during electrophysiologic testing. Am J Cardiol 1987;59:45E-98E.
5. Graboys TB, Podrid PJ, Lown B. Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. Am Heart J 1983;106:870-876.
6. Horowitz LN, Spielman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, Brady PM, Kay HR. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 1985;6:1402-1407.
7. Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986;57:124-127.
8. Blevins RD, Kerin NZ, Benaderet D, Frumin M, Faitel K, Jarandilla R, Rubenfire M. Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med 1987;147:1401-1404.
9. Brodsky MA, Allen BJ, Walker CJ, Casey TP, Luckett CR, Henry WL. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987;60:572-575.
10. Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50.
11. Santos AL, Aleixo AM, Landeiro J, Luis AS. Conversion of atrial fibrillation to sinus rhythm with amiodarone. Acta Med Port 1979;1:15-23.
12. Rowland E, McKenna WJ, Krikler DM. Amiodarone for the conversion of established atrial fibrillation and flutter. Br J Clin Pract 1986;40:39-41.
13. Zehender M, Hohnloser S, Muller B, Meinertz T, Just H. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. J Am Coll Cardiol 1992;19:1054-1059.
14. Haffajee CI, Love JC, Canada AT, Lesko LJ, Asdourian G, Alpert JS. Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circulation 1983;67:1347-1355.
15. Singh BN, Venkatesh N, Nademanee K, Josephson MA, Kannan R. The historical development, cellular electrophysiology and pharmacology of amiodarone. Prog Cardiovasc Dis 1989;31:249-280.
16. Rotmensch HH, Belhassen B, Swanson BN, Shoshani D, Spielman SR, Greenspon AJ, Greenspan AM, Vlasses PH, Horowitz LN. Steady-state plasma amiodarone concentrations relationships with antiarrhythmic efficacy and toxicity. Ann Intern Med 1984;101:642-649.
17. Torres V, Tepper D, Flowers D, Wynn J, Lam S, Keefe D, Miura DS, Somberg JC. QT prolongation and the antiarrhythmic efficacy of amiodarone. J Am Coll Cardiol 1986;7:142-147.
18. Greenberg ML, Lerman BB, Shipe JR, Kaiser DL, DiMarco JP. Relation between amiodarone and desethylamiodarone plasma concentrations and electrophysiologic effects, efficacy and toxicity. J Am Coll Cardiol 1987;9:1148-1155.
19. Falik R, Flores BT, Shaw L, Gibson GA, Josephson ME, Marchlinski FE. Relationship of steady-state plasma concentrations of amiodarone and desethylamiodarone to therapeutic efficacy and adverse effects. Am J Med 1987;82:1102-1108.
20. Greene LH. The efficacy of amiodarone in the treatment of ventricular tachycardia or ventricular fibrillation. Prog Cardiovasc Dis 1989;31:319-354.
21. Pollak PT, Sharma AD, Carruthers SG. Correlation of amiodarone dosage, heart rate, QT interval and corneal microdepositswith plasma amiodarone and desethylamiodarone concentrations. Am J Cardiol 1989;64:1138-1143.
22. Holt DW, Tucker GT, Jackson PR, Storey GCA. Amiodarone pharmacokinetics. Am Heart J 1983;106:840-846.
23. Mostow ND, Rakita L, Vrobel TR, Noon DL, Blumer J. Amiodarone: correlation of plasma concentration with suppression of complex ventricular ectopic activity. Am J Cardiol 1984;54:569-574.
24. Nattel S, Davies M, Quantz M. The antiarrhythmic efficacy of amiodarone and desethylamiodarone, alone and in combination, in dogs with acute myocardial infarction. Circulation 1988;77:200-208.
25. Balser JR, Bennett PB, Hondeghem LM, Roden DM. Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quindine and amiodarone Circ Res 1991;69:519-529.
26. Nattel S, Talajic M, Fermini B, Roy D. Amiodarone: pharmacology, clinical actions, and relationships between them. J Cardiovasc Electrophysiol 1992;3:266-280.
27. Heger JJ, Prystowsky EN, Zipes DP. Relationship between amiodarone dosage, drug concentrations, and adverse side effects. Am Heart J 1983;106:ndash;935.
28. Venkatesh N, Somani P, Bersohn M, Phair R, Kato R, Singh BN. Electropharmacology of amiodarone: absence of relationship to plasma, myocardial, and cardiac sarcolemmal membrane drug concentrations. Am Heart J 1986;112:916-922.
29. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, Woosley RL. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosage regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J 1995;16:521-528.